Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

This phase 2 trial tests a drug called sacituzumab tirumotecan (Sac-TMT) in 30 people with advanced thymic carcinoma that has worsened after platinum chemotherapy. Participants receive the drug every 2 weeks, and doctors check tumor response every 6 weeks. The study aims to see i…

This phase 2 trial tests a new drug called SKB571 combined with other cancer medicines in 150 people with non-small cell lung cancer. The goal is to see if the combination can shrink tumors and control the disease. Participants will receive the drugs by injection or mouth, and re…

This study tests an experimental drug, SKB118, in about 332 adults aged 18–75 with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The trial has three stages: finding the right dose,…

This study tests a new drug called SKB565 in 180 adults (ages 18-75) with advanced solid tumors that have not responded to standard treatments or are not eligible for them. The goal is to see if the drug is safe and can shrink tumors. The study has three parts: finding the right …

This study tests a new drug called SKB571 in 120 adults with gastrointestinal tumors. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for side effects and cancer progression. The study is not yet recruiting.

This study tests a new drug combination (SKB315 plus an immunotherapy) in people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. About 80 participants in China will receive the treatment to see if it shrinks tumors. The goal is to cont…